News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Yan Leyfman: Can bendamustine replace Flu/Cy as lymphodepleting chemotherapy before CAR-T in relapsed/refractory NHL
Yan Leyfman
Jun 18, 2025, 23:49

Yan Leyfman: Can bendamustine replace Flu/Cy as lymphodepleting chemotherapy before CAR-T in relapsed/refractory NHL

Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:

“New Study Alert: CAR-T Prep Reimagined! Can bendamustine replace Flu/Cy as lymphodepleting chemotherapy before CAR-T in relapsed/refractory NHL?
In a large real-world study (n=265), bendamustine showed:
  •  Comparable OS and PFS
  •  Less severe neutropenia (71% vs. 17%)
  •  Greater feasibility in outpatient settings
A promising alternative amidst global fludarabine shortages. Time to rethink how we prep for CART therapy? Kaplan-Meier and Cox models adjusted for CAR-T product, year, subtype, and steroid use.”

Title: Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma

Authors: Uttam K. Rao, Navneet S. Majhail, Betsy Blunk, Karin Abernathy, Carlos Bachier, Vikas Bhushan, Jose Carlos Cruz, Mohammed Elayan, Tara Gregory, Charles F. LeMaistre, Shahbaz A. Malik, Casey Martin, Meredith Mattlin, Gabrielle Blade, Michael B. Maris, John Mathews, Luke Mountjoy, Jeremy M. Pantin, Aravind Ramakrishnan, Paul Shaughnessy, Minoo Battiwalla

Read the Full Article.

Yan Leyfman

More posts featuring Yan Leyfman.

Aravind Ramakrishnan Betsy Blunk cancer Carlos Bachier Casey Martin Charles F. LeMaistre Gabrielle Blade Jeremy M. Pantin John Mathews Jose Carlos Cruz Karin Abernathy Luke Mountjoy Meredith Mattlin Michael B. Maris Minoo Battiwalla Mohammed Elayan Navneet S. Majhail OncoDaily Oncology Paul Shaughnessy Shahbaz A. Malik Tara Gregory Uttam K. Rao Vikas Bhushan
Special Coverage
Insight
Jun 18, 2025, 23:49
Yan Leyfman: Can bendamustine replace Flu/Cy as lymphodepleting chemotherapy before CAR-T in relapsed/refractory NHL
Science
Jun 18, 2025, 16:57
Mazvita Sengayi-Muchengeti Shares Anishka Ramadhar’s Study on Gastric Cancer Pathways in South Africa
Blog
Jun 18, 2025, 16:23
David Sebag-Montefiore: Join the 3rd International Multidisciplinary Anal Cancer Conference at the University of Leeds
Blog
Jun 18, 2025, 15:55
How Associate Professor Simon Chu is Rewriting the Story For a Rare Form of Ovarian Cancer - OCRF
Insight
Jun 18, 2025, 15:34
Amol Akhade: Top Sessions to Watch at ESMO GI 2025 – Clinical Innovation Meets Pragmatism
Insight
Jun 18, 2025, 15:32
Filippo Alongi Shared Study on Real-World Safety and Feasibility of 1.5 T MR-Guided Daily Adapted Radiotherapy in 1000 Patients
Insight
Jun 18, 2025, 15:30
ESTRO Highlighted 5-Year ABLATIVE Trial Results on MRI-Guided Single-Dose Breast Irradiation
Blog
Jun 18, 2025, 15:21
Carmen Monge-Montero Highlights Cancer Survivorship and Advocacy at Latest Episode of MANO Podcast
Blog
Jun 18, 2025, 15:15
Elen Baloyan: It Was A Pleasure To Be Invited to the Youth Cancer Europe’s Equity, Diversity and Inclusion Forum
Insight
Jun 18, 2025, 15:13
Nico Gagelmann: Closing the Gap - PTCy Boosts Survival After Mismatched Stem Cell Transplants
Blog
Jun 18, 2025, 15:10
Gerard Walls: Absolutely Epic ESTRO Breur Award Lecture From Professor Corinne Faivre-Finn Last Week
Opinion
Jun 18, 2025, 15:08
Razelle Kurzrock: Once Again, DART Hits A Target